Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2002
04/18/2002WO2002030413A1 Pharmaceutical solutions of modafinil compounds
04/18/2002WO2002030412A1 Compositions containing tryptamines, carotenoids and tocotrienols having synergistic antioxidant
04/18/2002WO2002030411A2 Treatment of apoptotic cell death
04/18/2002WO2002030410A2 Suppression of cyclin kinase activity for prevention and treatment of infections
04/18/2002WO2002030409A2 Methods for the treatment of a traumatic central nervous system injury
04/18/2002WO2002030408A2 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers
04/18/2002WO2002030407A1 ESTROGEN RECEPTOR-β LIGANDS
04/18/2002WO2002030406A2 Use of antagonists or partial agonists of 5ht1a receptors for the preparation of a medicament for treatment and prevention of gastrointestinal diseases
04/18/2002WO2002030405A2 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
04/18/2002WO2002030404A2 Combination therapy for premenstrual symptoms
04/18/2002WO2002030399A2 Polymer controlled delivery of a therapeutic agent
04/18/2002WO2002030396A1 Medication delivery devices
04/18/2002WO2002030395A1 Topical antibiotic composition for treatment of eye infection
04/18/2002WO2002030394A2 Medicinal aerosol formulations
04/18/2002WO2002030389A1 Novel tiotropium-containing inhalation powder
04/18/2002WO2002030385A2 Anti-inflammatory active ingredients
04/18/2002WO2002030377A2 Product for cleaning teeth and/or the mouth
04/18/2002WO2002030366A1 Melanogenesis inhibitors and whitening agents comprising ergosterol derivative and compositions containing ergosterol derivative
04/18/2002WO2002030358A2 Modulation of ccr4 function
04/18/2002WO2002030357A2 Compounds and methods for modulating ccr4 function
04/18/2002WO2002030356A2 Synthesis of epothilones and relates analogs
04/18/2002WO2002030355A2 Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
04/18/2002WO2002030354A2 Uridine therapy for patients with elevated purine levels
04/18/2002WO2002030353A2 NF-λB INHIBITORS
04/18/2002WO2002030257A2 Normalization of defective t cell responsiveness through manipulation of thymic regeneration
04/18/2002WO2002017914A3 Fused pyrrolocarbazoles against inflammation
04/18/2002WO2002012210A9 Biphenyl derivatives and their use as ppar-gamma receptor activators
04/18/2002WO2002011697A8 A method of preparing a pharmaceutical composition
04/18/2002WO2002011668A3 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
04/18/2002WO2002009815A3 New pharmaceutical composition
04/18/2002WO2002009814A3 New use of lipase inhibitors
04/18/2002WO2002009682A3 Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure
04/18/2002WO2002009679A3 Use of 13-cis retinoic acid for the treatment of emphysema
04/18/2002WO2002008217A3 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
04/18/2002WO2002008177A8 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives
04/18/2002WO2002007738A8 Combinations of chitosan and psyllium for synergistic adsorption of triglyceride and cholesterol
04/18/2002WO2002007721A3 Use of cox-2 inhibitors for preventing immunodeficiency
04/18/2002WO2002003995A3 Treatment of male sexual dysfunction
04/18/2002WO2002002541A3 Inhibitors of copper-containing amine oxidases
04/18/2002WO2002000201A3 Method for preparing a composition
04/18/2002WO2002000163A3 The method of treating drug resistant mycobacterium tuberculosis infection
04/18/2002WO2001096353A3 3'-PRODRUGS OF 2'-DEOXY-β-L-NUCLEOSIDES
04/18/2002WO2001093902A3 Immunostimulatory rna/dna hybrid molecules
04/18/2002WO2001093806A3 HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS
04/18/2002WO2001091748A3 Methods for prevention of ulcers and improving physiological performance
04/18/2002WO2001091732A3 Medicament for combating respiratory depression
04/18/2002WO2001087830A3 Substituted thioacetamides
04/18/2002WO2001087272A3 Encapsulating a toxic core within a non-toxic region in an oral dosage form
04/18/2002WO2001087229A3 Treating infections
04/18/2002WO2001082969A3 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
04/18/2002WO2001081574A3 Regulation of nf-at interacting protein nip 45 variant
04/18/2002WO2001080807A3 Medicine containing polysaccharide substances for activating apoptosis
04/18/2002WO2001077357A3 Chromosomal vectors and uses thereof
04/18/2002WO2001072289A3 Medicament for the stimulation of leucopoiesis and treatment of tumour and protozoan diseases acarinosis and arthropod-borne diseases and a method for production thereof
04/18/2002WO2001070209A3 Mono- and disaccharides for the treatment of nitric oxide related disorders
04/18/2002WO2001068912A3 Diagnosis of diseases associated with tumor suppressor genes and oncogenes
04/18/2002WO2001068570A3 Il-8 receptor antagonists
04/18/2002WO2001068569A3 Il-8 receptor antagonists
04/18/2002WO2001068075A3 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
04/18/2002WO2001068070A3 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
04/18/2002WO2001066595A3 Human fgf-23 gene and gene expression products
04/18/2002WO2001064681A3 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
04/18/2002WO2001062709A3 Use of 2-phenylene diamine derivatives for the treatment of infections
04/18/2002WO2001060400A3 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease
04/18/2002WO2001060378A3 Antiadhesive carbohydrates
04/18/2002WO2001060377A3 Methods for treatment of lysosomal storage diseases using biphosphonates
04/18/2002WO2001060345A3 Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator
04/18/2002WO2001060318A3 Protection of the female reproductive system from natural and artificial insults
04/18/2002WO2001058916A3 Antibodies to ccr5
04/18/2002WO2001058893A3 Indol-3-yl derivatives and their use as integrin inhibitors
04/18/2002WO2001055101A3 A new process for the preparation of latanoprost
04/18/2002WO2001052828A3 Glutamine prevention of delayed-onset irinotecan-induced diarrhea
04/18/2002WO2001051025A3 Formulations of active components in the form of a solid dispersion
04/18/2002WO2001045691A3 Method of treating gastrointestinal tract disease with purinergic receptor agonists
04/18/2002WO2001040271A3 Cancer associated antigens and uses therefor
04/18/2002WO2001039738A3 Use of flavones and/or isoflavones from plant extracts
04/18/2002WO2001034202A3 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells
04/18/2002WO2001026656A3 5-membered heterocycle derivatives and use thereof as monoamine oxidase inhibitors
04/18/2002WO2001026644A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto
04/18/2002WO2001025437A3 Growth factor polypeptides and nucleic acids encoding same
04/18/2002WO2001005253A8 Compositions, kits, and methods for providing and maintaining energy and mental alertness
04/18/2002WO2000071752A9 Assay for the detection of paclitaxel resistant cells in human tumors
04/18/2002WO2000070341A9 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer
04/18/2002WO2000066106A9 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
04/18/2002US20020045777 Used to treat hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.
04/18/2002US20020045774 Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain
04/18/2002US20020045772 E.g., 2 beta-(2-iodoethyloxy)-1 alpha ,3 beta ,25-tris(triethylsilyloxy)cholesta-5,7-diene
04/18/2002US20020045768 Preparation of cyclohexene derivatives intermediates for carotinoids using a mixture of zinc and a salt of ammonium, copper, alkali metal or alkaline earth metal as reducing agent
04/18/2002US20020045765 Tocopherol derivatives and method for preparation thereof
04/18/2002US20020045761 Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them
04/18/2002US20020045759 E.g., N-(2-Phenylsulfonyl-1-ethyl)-3-(4-Cyanophenyl)-2,3-dihydro-imidazo(2,1 -b)thiazole-5-carboxamide hydrochloride; treating cancer, neurofibromin benign proliferative disorder, retinal vascularization, and hepatitis delta
04/18/2002US20020045753 E.g., (S)-N-(4-(4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2 -yl)-carbonyl)-1-piperazinyl)phenyl)-2-thiophenecarboximidamide , or a salt thereof.
04/18/2002US20020045749 Antibacterial agents
04/18/2002US20020045747 Treating Alzheimer's disease both prophylactically and therapeutically
04/18/2002US20020045669 Novel class of polyamines without the side effects of Class I-IV compounds
04/18/2002US20020045668 Compositions for sustained release of analgesic agents, and methods of making and using the same
04/18/2002US20020045667 Non-toxic antimicrobial compositions and methods of use
04/18/2002US20020045665 Prostaglandin compositions and methods of treatment for male erectile dysfunction
04/18/2002US20020045664 Estrogen mimetics lacking reproductive tract effects
04/18/2002US20020045663 Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine